Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.

AIMS/HYPOTHESIS: Translation of genetic association signals into molecular mechanisms for diabetes has been slow. The glucokinase regulatory protein (GKRP; gene symbol GCKR) P446L variant, associated with inverse modulation of glucose- and lipid-related traits, has been shown to alter the kinetics o...

Full description

Bibliographic Details
Main Authors: Rees, MG, Wincovitch, S, Schultz, J, Waterstradt, R, Beer, N, Baltrusch, S, Collins, F, Gloyn, A
Format: Journal article
Language:English
Published: 2012
_version_ 1797099008208928768
author Rees, MG
Wincovitch, S
Schultz, J
Waterstradt, R
Beer, N
Baltrusch, S
Collins, F
Gloyn, A
author_facet Rees, MG
Wincovitch, S
Schultz, J
Waterstradt, R
Beer, N
Baltrusch, S
Collins, F
Gloyn, A
author_sort Rees, MG
collection OXFORD
description AIMS/HYPOTHESIS: Translation of genetic association signals into molecular mechanisms for diabetes has been slow. The glucokinase regulatory protein (GKRP; gene symbol GCKR) P446L variant, associated with inverse modulation of glucose- and lipid-related traits, has been shown to alter the kinetics of glucokinase (GCK) inhibition. As GCK inhibition is associated with nuclear sequestration, we aimed to determine whether this variant also alters the direct interaction between GKRP and GCK and their intracellular localisation. METHODS: Fluorescently tagged rat and human wild-type (WT)- or P446L-GCKR and GCK were transiently transfected into HeLa cells and mouse primary hepatocytes. Whole-cell and nuclear fluorescence was quantified in individual cells exposed to low- or high-glucose conditions (5.5 or 25 mmol/l glucose, respectively). Interaction between GCK and GKRP was measured by sensitised emission-based fluorescence resonance energy transfer (FRET) efficiency. RESULTS: P446L-GKRP had a decreased degree of nuclear localisation, ability to sequester GCK and direct interaction with GCK as measured by FRET compared with WT-GKRP. Decreased interaction was observed between WT-GKRP and GCK at high compared with low glucose, but not between P446L-GKRP and GCK. Rat WT-GKRP and P446L-GKRP behaved quite differently: both variants responded to high glucose by diminished sequestration of GCK but showed no effect of the P446L variant on nuclear localisation or GCK sequestration. CONCLUSIONS/INTERPRETATION: Our study suggests the common human P446L-GKRP variant protein results in elevated hepatic glucose uptake and disposal by increasing active cytosolic GCK. This would increase hepatic lipid biosynthesis but decrease fasting plasma glucose concentrations and provides a potential mechanism for the protective effect of this allele on type 2 diabetes risk.
first_indexed 2024-03-07T05:17:38Z
format Journal article
id oxford-uuid:ddc0be79-b7fd-4b70-8e8a-d326ff224b4e
institution University of Oxford
language English
last_indexed 2024-03-07T05:17:38Z
publishDate 2012
record_format dspace
spelling oxford-uuid:ddc0be79-b7fd-4b70-8e8a-d326ff224b4e2022-03-27T09:27:21ZCellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ddc0be79-b7fd-4b70-8e8a-d326ff224b4eEnglishSymplectic Elements at Oxford2012Rees, MGWincovitch, SSchultz, JWaterstradt, RBeer, NBaltrusch, SCollins, FGloyn, AAIMS/HYPOTHESIS: Translation of genetic association signals into molecular mechanisms for diabetes has been slow. The glucokinase regulatory protein (GKRP; gene symbol GCKR) P446L variant, associated with inverse modulation of glucose- and lipid-related traits, has been shown to alter the kinetics of glucokinase (GCK) inhibition. As GCK inhibition is associated with nuclear sequestration, we aimed to determine whether this variant also alters the direct interaction between GKRP and GCK and their intracellular localisation. METHODS: Fluorescently tagged rat and human wild-type (WT)- or P446L-GCKR and GCK were transiently transfected into HeLa cells and mouse primary hepatocytes. Whole-cell and nuclear fluorescence was quantified in individual cells exposed to low- or high-glucose conditions (5.5 or 25 mmol/l glucose, respectively). Interaction between GCK and GKRP was measured by sensitised emission-based fluorescence resonance energy transfer (FRET) efficiency. RESULTS: P446L-GKRP had a decreased degree of nuclear localisation, ability to sequester GCK and direct interaction with GCK as measured by FRET compared with WT-GKRP. Decreased interaction was observed between WT-GKRP and GCK at high compared with low glucose, but not between P446L-GKRP and GCK. Rat WT-GKRP and P446L-GKRP behaved quite differently: both variants responded to high glucose by diminished sequestration of GCK but showed no effect of the P446L variant on nuclear localisation or GCK sequestration. CONCLUSIONS/INTERPRETATION: Our study suggests the common human P446L-GKRP variant protein results in elevated hepatic glucose uptake and disposal by increasing active cytosolic GCK. This would increase hepatic lipid biosynthesis but decrease fasting plasma glucose concentrations and provides a potential mechanism for the protective effect of this allele on type 2 diabetes risk.
spellingShingle Rees, MG
Wincovitch, S
Schultz, J
Waterstradt, R
Beer, N
Baltrusch, S
Collins, F
Gloyn, A
Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title_full Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title_fullStr Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title_full_unstemmed Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title_short Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk.
title_sort cellular characterisation of the gckr p446l variant associated with type 2 diabetes risk
work_keys_str_mv AT reesmg cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT wincovitchs cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT schultzj cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT waterstradtr cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT beern cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT baltruschs cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT collinsf cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk
AT gloyna cellularcharacterisationofthegckrp446lvariantassociatedwithtype2diabetesrisk